SCHEMBL9364487

SCHEMBL9364487

COC(=O)C1CCc2cc(O)ccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.50
ESR1 P03372 8/20 0.44
ESR2 Q92731 7/20 0.44
CYP19A1 P11511 2/20 0.43
HSD17B1 P14061 4/20 0.42
LMNA P02545 2/20 0.42
CYP3A4 P08684 2/20 0.42
SHBG P04278 2/20 0.42
AKR1B10 O60218 1/20 0.42
CYP1A2 P05177 1/20 0.42
PGR P06401 1/20 0.42
SERPINA6 P08185 1/20 0.42
STS P08842 1/20 0.42
AR P10275 1/20 0.42
MAPT P10636 1/20 0.42
AKR1B1 P15121 1/20 0.42
NFKB1 P19838 1/20 0.42
SLC6A4 P31645 1/20 0.42
OPRM1 P35372 1/20 0.42
SNCA P37840 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2813805 0.91 ESR1 (0.47) AKR1C3ESR1ESR2CYP19A1HSD17B1
SCHEMBL30940153 0.91 ESR1 (0.47) AKR1C3ESR1ESR2CYP19A1HSD17B1
SCHEMBL2813791 0.88 AKR1C3 (0.42) AKR1C3ESR1ESR2HSD17B1MEN1
SCHEMBL2812915 0.88 NQO2 (0.48) AKR1C3ESR1ESR2CYP19A1CA1
SCHEMBL23670494 0.86 P2RX7 (0.46) AKR1C3HTR2B
SCHEMBL19469653 0.86 P2RX7 (0.46) AKR1C3HTR2B
SCHEMBL19285262 0.86 P2RX7 (0.46) AKR1C3HTR2B
SCHEMBL29552779 0.86 P2RX7 (0.46) AKR1C3HTR2B
SCHEMBL1530291 0.83 SRD5A1 (0.44) AKR1C3MAPTSLC6A4SLC6A3
SCHEMBL19469507 0.83 MTNR1A (0.50) CYP19A1CA1CA2ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249179-A1 Farnesoid X Receptor Agonists SMITHKLINE BEECHAM CORPORATION (US) 2010-09-30 US disclosed
EP-0275104-B1 Process for preparing 2,3-dihydro-1H-imidazolylalkoxyindene derivatives and pharmaceutically acceptable salts, and intermediate therefor FERRER INT (ES) 1994-01-19 EP disclosed
US-4843165-A Process for preparing a 2,3-dihydro-1H-imidazolyl-ethoxy indene antithrombotic agent and its pharmaceutically acceptable salts FERRER INTERNACIONAL S.A. (ES) 1989-06-27 US disclosed
EP-0275104-A2 Process for preparing 2,3-dihydro-1H-imidazolylalkoxyindene derivatives and pharmaceutically acceptable salts, and intermediate therefor FERRER INTERNACIONAL, S.A. (ES) 1988-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249179-A1 Farnesoid X Receptor Agonists NR1H4, NR1H3, NR1H2 AKR1C3 510/4885ESR1 451/4885ESR2 251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.